Abstract:Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare autosomal recessive neurometabolic disorder leading to severe combined serotonin, dopamine, norepinephrine, and epinephrine deficiency. We report on a female patient with borderline functioning and sporadic clear-cut focal to bilateral seizures from age 10 years. A neuropsychological assessment highlighted a mild impairment in executive functions, affecting attention span and visual-spatial abilities. Following the diagnosis of epilepsy with a presumed genetic etiology, we applied a diagnostic approach inclusive of a next-generation sequencing (NGS) gene panel, which uncovered two variants in trans in the DOPA decarboxylase (DDC) gene underlying an AADC deficiency. This compound heterozygous genotype was associated with a mild reduction of homovanillic acid, a low level of the norepinephrine catabolite, and a significant reduction of 5-hydroxyindoleacetic acid in cerebrospinal fluid. Remarkably, 3-O-methyldopa (3-OMD) and 5-hydroxytryptophan were instead increased. During the genetically guided re-evaluation process, some mild signs of dysautonomic dysfunction (nasal congestion, abnormal sweating, hypotension and fainting, excessive sleepiness, small hands and feet, and increased levels of prolactin, tiredness, and fatigue), more typical of AADC deficiency, were evaluated with new insight. Of the two AADC variants, the R347Q has already been characterized as a loss-of-function with severe catalytic impairments, while the novel L391P variant has been predicted to have a less severe impact. Bioinformatic analyses suggest that the amino acid substitution may affect affinity for the PLP coenzyme. Thus, the genotype corresponds to a phenotype with mild and late-onset symptoms, of which seizures were the clinical sign, leading to medical attention. This case report expands the spectrum of AADC deficiency phenotypes to encompass a less-disabling clinical condition including borderline cognitive functioning, drug-responsive epilepsy, and mild autonomic dysfunction.

Case Report: Rapid Treatment of Uridine-Responsive Epileptic Encephalopathy Caused by CAD Deficiency

A Patient with CAD Deficiency Responsive to Uridine and Literature Review

CAD mutations and uridine-responsive epileptic encephalopathy

Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature

Case Report: Pediatric Anti-Gamma Aminobutyric Acid-B Receptor Encephalitis with Benign Prognosis.

Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation

Adolescent-onset epilepsy and deterioration associated with CAD deficiency: A case report

Fourteen Cases of Cerebral Creatine Deficiency Syndrome in Children: a Cohort Study in China.

A Treatable Genetic Disease Caused by CAD Mutation

Clinical Diagnosis, Treatment, and ALDH7A1 Mutations in Pyridoxine-Dependent Epilepsy in Three Chinese Infants

A Chinese DADA2 Patient: Report of Two Novel Mutations and Successful HSCT

Case report: Early (molecular) diagnosis is the clue: report on ALDH7A1 deficiency in newborns

New Neuroimaging Findings in Patients with Molybdenum Cofactor Deficiency Type A: A Case Report and Literature Review

First Reported Chinese Case of Guanidinoacetate Methyltransferase Deficiency in a 4-Year-old Child.

[Genetic Analysis and Treatment for an Infant with Cerebral Creatine Deficiency Syndrome Type 2].

Clinical Analysis of Pyridoxine-Dependent Epilepsy in a Child and ALDH7A1 Mutation

Neonatal maple syrup urine disease in China: two novel mutations in the BCKDHB gene and literature review

Case report: Childhood epilepsy and borderline intellectual functioning hiding an AADC deficiency disorder associated with compound heterozygous DDC gene pathogenic variants

Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay

Case Report: Cerebral folate deficiency caused by FOLR1 variant

[Psychomotor Retardation and Intermitent Convulsions for 8 Months in an Infant].